9781509916764 (online) 9781509916696 (hardback) 9781509916733 (electronic book) 9781509916726 (PDF)
Civil justice systems ; v. 8.
"This book examines how regulatory and liability mechanisms have impacted upon product safety decisions in the pharmaceutical and medical devices sectors in Europe, the USA and beyond since the 1950s. Thirty-five case studies illustrate the interplay between the regulatory regimes and litigation. Observations from medical practice have been the overwhelming means of identifying post-marketing safety issues. Drug and device safety decisions have increasingly been taken by public regulators and companies within the framework of the comprehensive regulatory structure that has developed since the 1960s. In general, product liability cases have not identified or defined safety issues, and function merely as compensation mechanisms. This is unsurprising as the thresholds for these two systems differ considerably; regulatory action can be triggered by the possibility that a product might be harmful, whereas establishing liability in litigation requires proving that the product was actually harmful. As litigation normally post-dates regulatory implementation, the 'private enforcement' of public law has generally not occurred in these sectors. This has profound implications for the design of sectoral regulatory and liability regimes, including associated features such as extended liability law, class actions and contingency fees. This book forms a major contribution to the academic debate on the comparative utility of regulatory and liability systems, on public versus private enforcement, and on mechanisms of behaviour control."--Bloomsbury Publishing.
Compliant with Level AA of the Web Content Accessibility Guidelines. Content is displayed as HTML full text which can easily be resized or read with assistive technology, with mark-up that allows screen readers and keyboard-only users to navigate easily.
Bibliography, etc. Note
Includes bibliographical references and index.
Formatted Contents Note
1. Introduction I. The legal context A. Basis of liability B. Litigation systems C. Funding and costs D. US: the class action and MDL E. Europe F. Settlement schemes 2. The regulation of medicines and medical devices I. Medicinal products A. Historical drug/pharmaceutical regulation in the UK B. European regulation of medicinal products C. European regulation of medical devices D. General product safety regulation in Europe E. Medicinal product regulation in the US F. US regulation of medical devices 3. Detailed case descriptions and regulatory histories I. Teratogens and foetal damage A. Thalidomide (alpha-phthalimido-glutarimide) B. Hormonal pregnancy tests - including primodos C. Diethylstilboestrol (DES) D. Epilim/depakote/depakene (sodium valproate, valproic acid, magnesium valproate, valproate semisodium or valpromide) E. Accutane/roaccutane (isotretinoin) II. Contraceptives and hormone replacement therapy A. Gravigard or copper 7 intrauterine device B. Third-generation oral contraceptives C. Norplant (levonorgestrel) D. Hormone replacement therapy III. Vaccines A. DTP vaccine B. MMR vaccine IV. Neuromodulators A. Benzodiazepines B. Merital (nomifensine) C. Selective serotonin reuptake inhibitors D. Sabril (vigabatrin) E. Mirapexin/sifrol/daquiran (pramipexole) V. Non-steroidal anti-inflammatories A. Opren (benoxaprofen) B. Vioxx (rofecoxib) VI. Pancreatic function (endocrine and exocrine) and obesity treatments A. Adifax/Isomeride/Redux (dexfenfluramine) and Ponderax (fenfluramine) B. Mediator (benfluorex) C. Human Insulin D. Pancreatic Enzymes VII. Contaminated Human-Tissue-Derived products A. Blood products B. Human growth hormone VIII. Cardiovascular pharmaceuticals A. Eraldin (practolol) B. Manoplax (flosequinan) C. Lipobay (cerivastatin) IX. Anti-protozoan medications A. Emaform, entero-form or chinoform (clioquinol) B. Lariam (mefloquine) X. Breast and other cosmetic implants A. Dow-corning silicone implants B. Trilucent breast implants C. Poly implant prothese (PIP) hydrogel breast implants D. Poly implant prothese (PIP) IMGHC silicone breast implants XI. Urinary incontinence and pelvic prolapse treatments A. Micturin (terodiline) B. Urogynaecological mesh 4. Conclusions I. Prevention is better than a cure II. Adverse event reporting III. Correlation or causation? IV. Thresholds V. Product withdrawals VI. Compensation or redress? VII. Public regulation v private regulation A. Compensation - redress B. Deterrence VIII. Conclusions.